# Reasoning Log: Will the community prediction be higher than 27.00% on 2026-03-13 for the Metaculus question "Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?"?

*Generated: 2026-03-03T19:10:27.685834+00:00*


## 💭 Thinking

This is a meta-prediction question about whether the Metaculus community prediction (CP) for "Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?" will be higher than 27.00% on 2026-03-13.

Key details:
- Current CP as of 2026-03-01: 27.00%
- Threshold: 27.00% (strictly higher than)
- Resolution date: 2026-03-13 15:41:01
- The question was just published today (2026-03-03)
- The question closes today (2026-03-03 20:21:27)


- I need to pull the CP history and examine the underlying question to understand what might drive movement in the prediction.

## 💬 Response

I need to analyze this meta-prediction question. Let me gather the key data.

## 🔧 Tool: mcp__markets__get_cp_history


## 🔧 Tool: mcp__markets__get_metaculus_questions


## 🔧 Tool: mcp__search__web_search


```json
{
  "post_id": 41169,
  "days": 60
}
```

### 📋 Result

```
Failed to fetch CP history: Client error '403 Forbidden' for url 'https://www.metaculus.com/api/aggregation_explorer/?post_id=41169&aggregation_methods=recency_weighted'
For more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403
```

```json
{
  "post_id_list": [
    41169
  ]
}
```

### 📋 Result

```
{"post_id": 41169, "title": "Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?", "type": "binary", "url": "https://www.metaculus.com/questions/41169",
"background_info": "[CRISPR](https://en.wikipedia.org/wiki/CRISPR_gene_editing) is genetic engineering technique which allows the genomes of living organisms to be modified. Discovered in the 2000s
and seeing further development during the 2010s and 2020s, the technology has undergone medical trials for conditions as varied as cancer, diabetes, AIDS and blindness, while also being used to create
gene edited food.\n\nAlthough numerous trials have taken place, only two conditions have had CRISPR treatments be approved by the FDA (US), MHRA (UK) or EMA (EU). Both conditions being inherited blood
disorders, the same treatment was separately approved for both [sickle cell disease](https://en.wikipedia.org/wiki/Sickle_cell_disease) and [beta
thalassemia](https://en.wikipedia.org/wiki/Beta_thalassemia), in which [hematopoietic stem cells](https://en.wikipedia.org/wiki/Hematopoietic_stem_cell) are removed from the body, edited using CRISPR
to disrupt repression of [fetal hemoglobin](https://en.wikipedia.org/wiki/Fetal_hemoglobin) production, and then infused back into the patient.", "resolution_criteria": "This question will resolve as
**Yes** if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other
than sickle cell disease and beta thalassemia before January 1, 2027.", "fine_print": "&#x20;Authorizations include emergency or temporary authorizations.", "num_forecasters": 743,
"community_prediction": null}
```

```json
{
  "query": "CRISPR gene editing therapy FDA approval 2026 new condition"
}
```

### 📋 Result

```
{"query": "CRISPR gene editing therapy FDA approval 2026 new condition", "results": [{"title": "UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies", "url":
"https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies", "snippet": "After teasing a new regulatory process for personalized genetic medicines at the end of
last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, like the one that treated critically ill baby KJ last year, formally embraced by the
agency.\nFor now, the new pathway focuses on genome editing and RNA-based methods\u2014like antisense oligonucleotides\u2014that target the underlying cause of a rare disease, the FDA said in a [Feb.
23 release](https://www.f", "api_data": null, "hint": null}, {"title": "Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects - PMC", "url":
"https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/", "snippet": "Abstract\nGenome editing has recently evolved from a theoretical concept to a powerful and versatile set of tools. The discovery and
implementation of CRISPR-Cas9 technology have propelled the field further into a new era. This RNA-guided system allows for specific modification of target genes, offering high accuracy and
efficiency. Encouraging results are being announced in clinical trials employed in conditions like sickle cell disease (SCD) and transfusion-dependent beta-thalassaemia (TDT). Th", "api_data": null,
"hint": null}, {"title": "FDA says a plausible mechanism can be enough for rare disease approval : NPR", "url": "https://www.npr.org/2026/02/23/nx-s1-5720948/fda-rare-disease-gene-therapy", "snippet":
"The FDA creates a quicker path for gene therapies\n![The Food and Drug Administration will consider approving treatments for rare diseases based on evidence they have a plausible
mechanism.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4994x3330+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-
brightspot.s3.amazonaws.com%2Fd6%2Fba%2F08fe934f4853a283a162fc192d1b%2Fap25225779123916.jpg)\nThe Food and Drug Administration will consider approving treatments for rare diseases", "api_data": null,
"hint": null}, {"title": "Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease - PMC", "url":
"https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/", "snippet": "Abstract\nSickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a \u03b2-globin chain mutation that causes
abnormal hemoglobin (HbS) polymerization and leads to severe complications. Current treatment options primarily focus on symptom management, with limited curative potential. Recently, Casgevy, the
first CRISPR/Cas9-based gene therapy for SCD, has received breakthrough FDA approval. Clinical trials have shown that Casgevy administered to patients aged older than or equal to 12 ", "api_data":
null, "hint": null}, {"title": "FDA\u2019s new \u2018plausible mechanism pathway\u2019 for personalized gene editing raises concerns", "url": "https://www.statnews.com/2026/01/26/fda-makary-prasad-
crispr-gene-editing-concerns-baby-kj/", "snippet": "![](https://www.statnews.com/wp-content/uploads/2026/01/03-20-2025-STAT-East-2091-645x645.jpg)\nWhen [Baby
KJ](https://www.statnews.com/2025/05/26/what-kj-muldoon-crispr-gene-editing-treatment-means-for-interventional-genetics/) was introduced to the world last year as the first recipient of a personalized
gene-editing treatment, the logical next question was: How can we get to more Baby KJs?\nIn November, six months after KJ\u2019s debut, top Food and Drug Administration officials Marty Makary and
Vin", "api_data": null, "hint": null}, {"title": "FDA unveils new regulatory roadmap for bespoke drug therapies | BioPharma Dive", "url": "https://www.biopharmadive.com/news/fda-plausible-mechanism-
pathway-n-of-1-crispr/805235/", "snippet": null, "api_data": null, "hint": null}, {"title": "FDA fleshes out new roadmap for testing personalized therapies | BioPharma Dive", "url":
"https://www.biopharmadive.com/news/fda-guidance-personalized-therapies-rare-diseases-hhs/812890/", "snippet": null, "api_data": null, "hint": null}, {"title": "CRISPR Clinical Trials: A 2025 Update -
Innovative Genomics Institute (IGI)", "url": "https://innovativegenomics.org/news/crispr-clinical-trials-2025/", "snippet": "![](https://innovativegenomics.org/wp-content/uploads/2025/06/clinical-
trials-2025-header-v1.jpg)\nFor [CRISPR](https://innovativegenomics.org/glossary/crispr/) clinical trials, 2025 seems like the best of times and the worst of times.\nThe best: a year and half ago, we
saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent [beta thalassemia](https://innovativegenomics.org/glossary/beta-
thalassemia/) (TBT). Since then, 50 activ", "api_data": null, "hint": null}, {"title": "CRISPR Clinical Trials to Follow", "url": "https://www.synthego.com/blog/crispr-clinical-trials/", "snippet":
"In 2023, we entered the second decade of the CRISPR revolution, and saw the [approval of Casgevy](https://ir.crisprtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-
us-fda-approval), the first CRISPR-based medicine to become widely available. The last several years have seen a marked increase in the number of genomic medicines in clinical development, and more of
these candidates are pushing into the clinic for the first time. So how many CRISPR clinical trials ar", "api_data": null, "hint": null}, {"title": "The FDA creates a quicker path for gene therapies |
NPR & Houston Public Media", "url": "https://www.houstonpublicmedia.org/npr/2026/02/23/nx-s1-5720948/the-fda-creates-a-quicker-path-for-gene-therapies/", "snippet": "![The Food and Drug Administration
will consider approving treatments for rare diseases based on evidence they have a plausible
mechanism.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4994x3330+0+0/resize/1200/quality/75/format/webp/?url=http%3A%2F%2Fnpr-
brightspot.s3.amazonaws.com%2Fd6%2Fba%2F08fe934f4853a283a162fc192d1b%2Fap25225779123916.jpg)\nThe Food and Drug Administration Monday unveiled the details of a new policy designed to make it easier
and quicker for patients with v", "api_data": null, "hint": null}]}
```

## 💬 Response

CP history is blocked (403). Let me try alternative approaches and search for more specific data about gene therapy approvals in the pipeline.

## 🔧 Tool: mcp__search__web_search


## 🔧 Tool: mcp__search__web_search


## 🔧 Tool: mcp__markets__get_coherence_links


```json
{
  "query": "gene editing therapy CRISPR FDA PDUFA approval date 2026"
}
```

### 📋 Result

```
{"query": "gene editing therapy CRISPR FDA PDUFA approval date 2026", "results": [{"title": "UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies", "url":
"https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies", "snippet": "After teasing a new regulatory process for personalized genetic medicines at the end of
last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, like the one that treated critically ill baby KJ last year, formally embraced by the
agency.\nFor now, the new pathway focuses on genome editing and RNA-based methods\u2014like antisense oligonucleotides\u2014that target the underlying cause of a rare disease, the FDA said in a [Feb.
23 release](https://www.f", "api_data": null, "hint": null}, {"title": "Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects - PMC", "url":
"https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/", "snippet": "Abstract\nGenome editing has recently evolved from a theoretical concept to a powerful and versatile set of tools. The discovery and
implementation of CRISPR-Cas9 technology have propelled the field further into a new era. This RNA-guided system allows for specific modification of target genes, offering high accuracy and
efficiency. Encouraging results are being announced in clinical trials employed in conditions like sickle cell disease (SCD) and transfusion-dependent beta-thalassaemia (TDT). Th", "api_data": null,
"hint": null}, {"title": "FDA Approves Vertex & CRISPR's Gene Editing Therapy | CAF", "url": "https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy", "snippet": "FDA Approves
Vertex-CRISPR Gene Therapy for Beta Thalassemia\nThe FDA has approved [Vertex and CRISPR\u2019s\ngene-editing therapy Casgevy](https://www.fiercepharma.com/pharma/vertex-crispr-win-early-fda-nod-gene-
therapy-casgevy-treat-beta-thalassemia) to treat Beta Thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology.\nVertex
Pharmaceuticals and CRISPR Therapeutics have [scored](https://investors.vrtx.com/news-releases/news-rele", "api_data": null, "hint": null}, {"title": "PDUFA Dates 2026: Complete FDA Calendar with AI
Approval Scores | PDUFA.BIO | PDUFA.BIO", "url": "https://www.pdufa.bio/pdufa-dates-2026", "snippet": "PDUFA Dates 2026: Complete FDA Drug Approval Calendar\n2026 is shaping up to be a landmark year
for biotech approvals. Track every PDUFA date, FDA decision deadline, and approval catalyst with ODIN's AI-powered approval probability scores. This calendar is your definitive guide to regulatory
catalysts that drive biotech stock moves.\nWhat Are PDUFA Dates and Why Do They Matter?\nPDUFA stands for Prescription Drug User Fee Act. When a pharmaceutical company submits a drug application (BLA
for biolog", "api_data": null, "hint": null}, {"title": "Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease - PMC", "url":
"https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/", "snippet": "Abstract\nSickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a \u03b2-globin chain mutation that causes
abnormal hemoglobin (HbS) polymerization and leads to severe complications. Current treatment options primarily focus on symptom management, with limited curative potential. Recently, Casgevy, the
first CRISPR/Cas9-based gene therapy for SCD, has received breakthrough FDA approval. Clinical trials have shown that Casgevy administered to patients aged older than or equal to 12 ", "api_data":
null, "hint": null}, {"title": "FDA says a plausible mechanism can be enough for rare disease approval : NPR", "url": "https://www.npr.org/2026/02/23/nx-s1-5720948/fda-rare-disease-gene-therapy",
"snippet": "The FDA creates a quicker path for gene therapies\n![The Food and Drug Administration will consider approving treatments for rare diseases based on evidence they have a plausible
mechanism.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4994x3330+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-
brightspot.s3.amazonaws.com%2Fd6%2Fba%2F08fe934f4853a283a162fc192d1b%2Fap25225779123916.jpg)\nThe Food and Drug Administration will consider approving treatments for rare diseases", "api_data": null,
"hint": null}, {"title": "FDA Decisions to Look For in 1H 2026 | CGTlive\u00ae", "url": "https://www.cgtlive.com/view/fda-decisions-look-1h-2026", "snippet": "![](https://cdn.sanity.io/images/0vv8moc6
/genetherapy/9b1b40bc81fc00eeb21179fe80ec2a22d6af7e25-800x500.jpg?w=350&fit=crop&auto=format)\n![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/9b1b40bc81fc00eeb21179fe80ec2a22d6af7e25-
800x500.jpg?w=350&fit=crop&auto=format)\nWe highlighted a few cell and gene therapies that are nearing or likely nearing key FDA decisions in the first half of 2026.\nAs 2026 kicks off, CGTLive\u00ae
is taking a look ahead at some of the most noteworthy cell and gene therapy p", "api_data": null, "hint": null}, {"title": "Celebrating a new, faster path to gene-editing medicines on demand", "url":
"https://www.statnews.com/2025/11/14/fda-gene-editing-medicines-on-demand-pathway/", "snippet": "![](https://www.statnews.com/wp-content/uploads/2022/02/AdobeStock_334418121-645x645.jpeg)\nIn May,
news [broke](https://www.nejm.org/doi/full/10.1056/NEJMoa2504747) of a biomedical first: the on-demand design and clinical use of a personalized gene editor for a baby boy born with a rare, severe
genetic condition. At the STAT Summit in October, the child\u2019s treating physician from the Children\u2019s Hospital of Philadelphia (CHOP) and the lead on developing the gene editor for him shared
the stage wit", "api_data": null, "hint": null}, {"title": "UPDATED: Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies", "url":
"https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies", "snippet": "In a highly anticipated article, FDA officials Vinay Prasad, M.D.,
and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.\nThe new program, called the
\u201cplausible mechanism pathway,\u201d is designed to offer a new way to market for personalized therapies, Prasad and Makary said at the beginning of a [New England Journal of
Medicine](https://www.nejm.org/doi/full/10.1056/NEJMsb2512695) article.\nTh", "api_data": null, "hint": null}, {"title": "Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins,
PDUFA date granted", "url": "https://www.fiercebiotech.com/biotech/landmark-approval-vertexs-crispr-drug-two-steps-closer-after-trial-wins-pdufa-date-granted", "snippet": "Vertex and CRISPR
Therapeutics\u2019 dream of getting the first-ever CRISPR gene editing therapy approved now seems within reach as the candidate [aced primary
endpoints](https://www.businesswire.com/news/home/20230609005104/en/Positive-Results-From-Pivotal-Trials-of-exa-cel-for-Transfusion-Dependent-Beta-Thalassemia-and-Severe-Sickle-Cell-Disease-Presented-
at-the-2023-Annual-European-Hematology-Association-EHA-Congress) in a pair of phase 3 trials mere hours after the FDA penciled in a decision date", "api_data": null, "hint": null}]}
```

```json
{
  "query": "Casgevy Verve CRISPR gene editing FDA BLA approval 2026 timeline"
}
```

### 📋 Result

```
{"query": "Casgevy Verve CRISPR gene editing FDA BLA approval 2026 timeline", "results": [{"title": "Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle
cell disease - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/", "snippet": "Abstract\nSickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a \u03b2-globin chain
mutation that causes abnormal hemoglobin (HbS) polymerization and leads to severe complications. Current treatment options primarily focus on symptom management, with limited curative potential.
Recently, Casgevy, the first CRISPR/Cas9-based gene therapy for SCD, has received breakthrough FDA approval. Clinical trials have shown that Casgevy administered to patients aged older than or equal
to 12 ", "api_data": null, "hint": null}, {"title": "Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY\u2122 (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease |
Vertex Pharmaceuticals Newsroom", "url": "https://news.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval", "snippet": null, "api_data": null, "hint":
null}, {"title": "Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY\u2122 (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease | Vertex Pharmaceuticals", "url":
"https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval", "snippet": null, "api_data": null, "hint": null}, {"title": "A gene editing
milestone: The FDA approves CASGEVY, the first CRISPR-based therapy", "url": "https://www.labiotech.eu/trends-news/casgevy-crispr-uk-approval/", "snippet": "A gene editing milestone: The FDA approves
CASGEVY, the first CRISPR-based therapy By Willow Shah-Neville 6 minutesmins December 6, 2023 -Updated: onJuly 21, 2025 6 minutesmins Share WhatsApp Twitter Linkedin Email Photo/Shutterstock
Newsletter Signup - Under Article / In Page\"*\" indicates required fieldsX/TwitterThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest
biotech news!By clicking this I agree to receive Labiotech's newsletter ", "api_data": null, "hint": null}, {"title": "Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY\u2122
(exagamglogene autotemcel) for the Treatment of Sickle Cell Disease | CRISPR Therapeutics", "url": "https://ir.crisprtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-
us-fda-approval", "snippet": null, "api_data": null, "hint": null}, {"title": "Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease - PubMed",
"url": "https://pubmed.ncbi.nlm.nih.gov/39118728/", "snippet": "Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease\n- PMID:
39118728\n-\nPMCID:\n[PMC11305803](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/) -\nDOI:\n[10.1097/MS9.0000000000002146](https://doi.org/10.1097/ms9.0000000000002146)\nRevolutionary
breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease\nAbstract\nSickle cell disease (SCD) is a hereditary hemoglobinopathy resulting from a \u03b2-globin
chain mutati", "api_data": null, "hint": null}, {"title": "CASGEVY", "url": "https://www.fda.gov/media/175179/download", "snippet": null, "api_data": null, "hint": null}, {"title": "FDA Approves
Vertex & CRISPR's Gene Editing Therapy | CAF", "url": "https://thalassemia.org/FDA-Approves-Vertex-CRISPRs-Gene-Editing-Therapy", "snippet": "FDA Approves Vertex-CRISPR Gene Therapy for Beta
Thalassemia\nThe FDA has approved [Vertex and CRISPR\u2019s\ngene-editing therapy Casgevy](https://www.fiercepharma.com/pharma/vertex-crispr-win-early-fda-nod-gene-therapy-casgevy-treat-beta-
thalassemia) to treat Beta Thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology.\nVertex Pharmaceuticals and CRISPR
Therapeutics have [scored](https://investors.vrtx.com/news-releases/news-rele", "api_data": null, "hint": null}, {"title": "RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy
CASGEVY\u2122 (exagamglogene autotemcel) - Roslin CT", "url": "https://www.roslinct.com/insights/roslinct-to-manufacture-first-ever-us-fda-approved-crispr-based-gene-therapy-casgevy-exagamglogene-
autotemcel/", "snippet": "RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY\u2122 (exagamglogene autotemcel)\nRoslinCT to manufacture this ground-breaking treatment
for patients with Sickle Cell Disease (SCD) in the US and in the UK for SCD and Transfusion-Dependent Beta Thalassemia\nEDINBURGH, UK, 11 December 2023 \u2013 RoslinCT, a cell and gene therapy
Contract Development and Manufacturing Organisation (CDMO) dedicated to developing therapies for patients who live with serious and life-threaten", "api_data": null, "hint": null}, {"title": "Summary
Basis for Regulatory Action Date: January 16, 2024 From:", "url": "https://www.fda.gov/media/175842/download", "snippet": null, "api_data": null, "hint": null}]}
```

```json
{
  "post_id": 41169
}
```

### 📋 Result

```
[]
```

## 💬 Response

Let me check the CGTlive article about FDA decisions in 1H 2026, and also look for specific gene editing therapies nearing approval.

## 🔧 Tool: mcp__search__fetch_url


## 🔧 Tool: mcp__search__web_search


```json
{
  "url": "https://www.cgtlive.com/view/fda-decisions-look-1h-2026",
  "prompt": "What gene editing therapies (specifically CRISPR or gene editing, not just gene therapy) have PDUFA dates or expected FDA decisions in 2026? List the therapies, conditions, and expected decision dates."
}
```

### 📋 Result

```
{"url": "https://www.cgtlive.com/view/fda-decisions-look-1h-2026", "content": "Based on the content provided, **none of the therapies listed are gene editing therapies (CRISPR or similar gene editing
technologies)**. \n\nAll the therapies mentioned are either:\n- **Gene therapies** (AAV vector-based delivery of genes): DTX401, clemidsogene lanparvovec (RGX-121)\n- **Cell therapies**: tabelecleucel
(tab-cel), deramiocel, marnetegragene autotemcel (RP-L201/Kresladi), Orca-T\n\nGene therapies deliver new genes but don't edit existing DNA, while gene editing (like CRISPR) makes precise changes to
the genome. The article does not mention any gene editing therapies with 2026 PDUFA dates.\n\n**Relevant links:**\n- [Capricor's complete response letter for
deramiocel](https://www.cgtlive.com/view/capricor-bla-dmd-cardiomyopathy-cell-therapy-deramiocel-slammed-crl)\n- [FDA's published CRL for
deramiocel](https://download.open.fda.gov/crl/CRL_BLA125842_20250709.pdf)\n- [Capricor's response to the
CRL](https://d1io3yog0oux5.cloudfront.net/_482bc4203ea211827b4af3a98e815915/capricor/files/pages/capricor/db/2325/description/CAPR_response_letter_FINAL_%281%29.pdf)\n- [Ultragenyx's rolling BLA
submission for DTX401](https://www.cgtlive.com/view/ultragenyx-rolling-bla-glycogen-storage-disease-gene-therapy-dtx401-front-fda)", "title": "FDA Decisions to Look For in 1H 2026 | CGTlive\u00ae"}
```

```json
{
  "query": "\"gene editing\" therapy approval 2026 MHRA \"EU\" commission new condition BLA NDA"
}
```

### 📋 Result

```
{"query": "\"gene editing\" therapy approval 2026 MHRA \"EU\" commission new condition BLA NDA", "results": [{"title": "Gene therapy - Health Research Authority", "url":
"https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/gene-therapy/", "snippet": "If your application is for ethical approval of a gene therapy clinical trial you must
apply to the [Gene Therapy Advisory Committee (GTAC)](/about-us/committees-and-services/res-and-recs/gene-therapy-advisory-committee/).\nGTAC is the UK national Research Ethics Committee (REC) for
gene therapy clinical research according to regulation 14(5) of The Medicines for Human Use (Clinical Trials) Regulations 2004.\nGene therapy medicinal products are defined in Part IV of Directive
2003/63/EC (amending D", "api_data": null, "hint": null}, {"title": "Gene Therapy Advisory Committee - Health Research Authority", "url": "https://www.hra.nhs.uk/about-us/committees-and-services/res-
and-recs/gene-therapy-advisory-committee/", "snippet": "If your application is for ethical approval of a gene therapy clinical trial you must apply to the Gene Therapy Advisory Committee (GTAC).\nGTAC
is the UK national REC for gene therapy clinical research according to regulation 14(5) of The Medicines for Human Use (Clinical Trials) Regulations 2004.\nGene therapy medicinal products\n![DNA
strand](https://s3.eu-west-2.amazonaws.com/www.hra.nhs.uk/media/images/DNA_strand.2e16d0ba.fill-100x100-c75.jpg)\n\u2026[a] gene therapy medicinal product means a produc", "api_data": null, "hint":
null}, {"title": "UK medicines regulator approves world-first gene-editing treatment for blood disorders | Imperial College Healthcare NHS Trust", "url": "https://www.imperial.nhs.uk/about-us/news/uk-
medicines-regulator-approves-world-first-gene-editing-treatment-for-blood-disorders", "snippet": "UK medicines regulator approves world-first gene-editing treatment for blood disorders\nThe UK has
become the first country in the world to approve gene editing as a potential cure for two inherited blood disorders.\nThe therapy is based on CRISPR gene editing and has been authorised by the
Medicines and Healthcare products Regulatory Agency (MHRA) following two global clinical trials, with Imperial College Healthcare NHS Trust leading the UK arm. The MHRA said the treatment could be
used on patie", "api_data": null, "hint": null}, {"title": "The FDA creates a quicker path for gene therapies | Georgia Public Broadcasting", "url": "https://www.gpb.org/news/2026/02/23/the-fda-
creates-quicker-path-for-gene-therapies", "snippet": "Section Branding\nHeader Content\nThe FDA creates a quicker path for gene therapies\nPrimary Content\nThe Food and Drug Administration Monday
unveiled the details of a new policy designed to make it easier and quicker for patients with very rare diseases to get cutting-edge treatments.\nThe [new guidance](https://www.fda.gov/regulatory-
information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific?utm_medium=email&utm_source", "api_data": null, "hint":
null}, {"title": "FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | HHS.gov", "url": "https://www.hhs.gov/press-room/fda-launches-framework-
accelerating-development-individualized-therapies-ultra-rare-diseases.html", "snippet": null, "api_data": null, "hint": null}, {"title": "FDA says a plausible mechanism can be enough for rare disease
approval : NPR", "url": "https://www.npr.org/2026/02/23/nx-s1-5720948/fda-rare-disease-gene-therapy", "snippet": "The FDA creates a quicker path for gene therapies\n![The Food and Drug Administration
will consider approving treatments for rare diseases based on evidence they have a plausible
mechanism.](https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4994x3330+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-
brightspot.s3.amazonaws.com%2Fd6%2Fba%2F08fe934f4853a283a162fc192d1b%2Fap25225779123916.jpg)\nThe Food and Drug Administration will consider approving treatments for rare diseases", "api_data": null,
"hint": null}, {"title": "UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies", "url": "https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-
gene-therapies", "snippet": "After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could
see custom CRISPR therapies, like the one that treated critically ill baby KJ last year, formally embraced by the agency.\nFor now, the new pathway focuses on genome editing and RNA-based
methods\u2014like antisense oligonucleotides\u2014that target the underlying cause of a rare disease, the FDA said in a [Feb. 23 release](https://www.f", "api_data": null, "hint": null}, {"title":
"WTAS: FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | HHS.gov", "url": "https://www.hhs.gov/press-room/wtas-fda-launches-framework-
accelerating-therapies-ultra-rare-diseases.html", "snippet": null, "api_data": null, "hint": null}, {"title": "Advancing CRISPR genome editing into gene therapy clinical trials: progress and future
prospects - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/", "snippet": "Abstract\nGenome editing has recently evolved from a theoretical concept to a powerful and versatile set of
tools. The discovery and implementation of CRISPR-Cas9 technology have propelled the field further into a new era. This RNA-guided system allows for specific modification of target genes, offering
high accuracy and efficiency. Encouraging results are being announced in clinical trials employed in conditions like sickle cell disease (SCD) and transfusion-dependent beta-thalassaemia (TDT). Th",
"api_data": null, "hint": null}, {"title": "7 New MHRA Guidances To Help You With Decentralized Manufacturing For Cell And Gene Therapies", "url": "https://www.cellandgene.com/doc/new-mhra-guidances-
to-help-you-with-decentralized-manufacturing-for-cell-and-gene-therapies-0001", "snippet": "7 New MHRA Guidances To Help You With Decentralized Manufacturing For Cell And Gene Therapies\nBy [Peter H.
Calcott](https://www.cellandgene.com/author/peter-h-calcott), Ph.D., FRSC, president and CEO, Calcott Consulting LLC\n![judges gavel on great britain flag-GettyImages-184134541 judges gavel on great
britain flag-GettyImages-184134541](https://vertassets.blob.core.windows.net/image/fe2cfd51/fe2cfd51-9d92-4b25-8c50-2b3050d3e374/375_250-judges_gavel_on_great_britain_flag_gettyimages_184134541.j",
"api_data": null, "hint": null}, {"title": "European Parliament and Council provisional deal on new genomic techniques brings relaxation of gene editing a step closer | Osborne Clarke", "url":
"https://www.osborneclarke.com/insights/european-parliament-and-council-provisional-deal-new-genomic-techniques-brings-relaxation", "snippet": "[Life Sciences and
Healthcare](https://www.osborneclarke.com/insights/sectors/life-sciences-and-healthcare)\nEuropean Parliament and Council provisional deal on new genomic techniques brings relaxation of gene editing a
step closer\nPublished on 16th December 2025\nTwo-tier categorisation of NGT plants endorsed alongside a patent ban rowback but patent transparency measures agreed\n![Blue and orange DNA
strands](https://oc-static.poweredbyproctors.co.uk/public/images/22/01/04/OC_KI_02_017.jpg?Versio", "api_data": null, "hint": null}, {"title": "European Parliament votes to ease regulation of gene-
edited crops | Science | AAAS", "url": "https://www.science.org/content/article/european-parliament-votes-ease-regulation-gene-edited-crops", "snippet": null, "api_data": null, "hint": null},
{"title": "Global status of genome editing versus transgenesis legislation in plants and the current EU situation | npj Science of Plants", "url": "https://www.nature.com/articles/s44383-025-00016-2",
"snippet": "Abstract\nPrecise breeding programs using new genome editing techniques have been developed to create plant varieties adapted to climate change. We studied the regulatory status of the 196
members of the United Nations (distinguishing the four UK countries) according to their legislation on transgenesis. We identified eight statuses for these techniques: \u2018allowed for any use\u2019
(24 countries, Argentina being the first in 2015), \u2018allowed for import\u2019 (1), \u2018legislation under discussion\u2019 (37), \u2018not all", "api_data": null, "hint": null}, {"title": "EN
BRIEFING EU Legislation in Progress", "url": "https://www.europarl.europa.eu/RegData/etudes/BRIE/2023/754549/EPRS_BRI(2023)754549_EN.pdf", "snippet": null, "api_data": null, "hint": null}, {"title":
"European Commission Adopts Proposal for the Biotech Act | Inside EU Life Sciences", "url": "https://www.insideeulifesciences.com/2025/12/17/european-commission-adopts-proposal-for-the-biotech-act/",
"snippet": "Introduction\nOn 16 December 2025, the European Commission (\u201cCommission\u201d) published its Proposal for a Regulation on establishing a framework of measures for strengthening the
Union\u2019s biotechnology and biomanufacturing sectors particularly in the area of health (\u201cBiotech Act\u201d) (see [here](https://health.ec.europa.eu/publications/proposal-regulation-establish-
measures-strengthen-unions-biotechnology-and-biomanufacturing-sectors_en)). The Proposal follows a public consultation held between August 2", "api_data": null, "hint": null}, {"title": "European
Union: Germline / Embryonic - Global Gene Editing Regulation Tracker", "url": "https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/eu-germline-embryonic/", "snippet": "Germline gene
editing for clinical purposes is banned, but it is unclear whether this ban applies to germline gene editing research. Germline editing is regulated by the [EU
Commission](https://ec.europa.eu/commission/index_en), the [European Medicines Agency](https://www.ema.europa.eu/en) (EMA) and the [Federation of European Academies of Medicine](http://www.feam-
site.eu/) (FEAM). In 2014, the [EU Clinical Trials Regulation](https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/r", "api_data": null, "hint": null}, {"title": "European Commission
proposes loosening rules for gene-edited plants | Science | AAAS", "url": "https://www.science.org/content/article/european-commission-proposes-loosening-rules-gene-edited-plants", "snippet": null,
"api_data": null, "hint": null}, {"title": "European Union: Therapeutic / Stem Cell - Global Gene Editing Regulation Tracker", "url": "https://crispr-gene-editing-regs-
tracker.geneticliteracyproject.org/eu-therapeutic-stem-cell/", "snippet": "Gene therapy is permitted but must comply with clinical trial regulations, the [EU Commission Regulation on advanced therapy
medicinal products](https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf), and the [European GMO Directive](https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:32001L0018), written in 2001, that outlines regulations for organisms altered through genetic modification. Requirements include environmental risk assessments", "api_data":
null, "hint": null}, {"title": "EU rethinks genome editing | Nature Plants", "url": "https://www.nature.com/articles/s41477-023-01505-x", "snippet": "The proposal by the European Commission for new
rules on gene-edited plants aims to align legislation with new developments in biotechnology. Yet concerns remain that have to do not only with biology.\nWhile mutation breeding has been in use since
the 1930s, and the risks of recombinant DNA technology were scientifically discussed during the Asilomar Conference in 1975, the public GMO debate started in the late 1970s over philosophical rather
than biological questions. In their 1977 book Who Shou", "api_data": null, "hint": null}, {"title": "Back to gene therapy: bringing the EU regulation into the future - ScienceDirect", "url":
"https://www.sciencedirect.com/science/article/pii/S1359644625001370", "snippet": "Gene therapies are rapidly advancing, challenging current ATMP Regulation.\n\u2022\nEC Regulatory Sandboxes may boost
regulatory alignment for innovative gene therapy.\n\u2022\nDecoupling ATMP regulation from production technology of active substance is crucial.\n\u2022\nEnhancing GTMP classification criteria is
vital for future regulatory readiness.\nThe current European framework for Advanced Therapy Medicinal Products (ATMPs), which also covers gene therapies, was established in 2007 at the dawn of the
biotechnolo", "api_data": null, "hint": null}, {"title": "Accelerated Approval Program | FDA", "url": "https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program", "snippet": null,
"api_data": null, "hint": null}, {"title": "FDA Drug Approval Decisions Expected in March 2026 - Gastroenterology Advisor", "url": "https://www.gastroenterologyadvisor.com/news/fda-drug-approval-
decisions-expected-in-march-2026/", "snippet": "The [Prescription Drug User Fee Act (PDUFA)](https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments) date refers to
the deadline set by the US Food and Drug Administration (FDA) for reviewing a [New Drug Application (NDA)](https://www.fda.gov/drugs/types-applications/new-drug-application-nda) or [Biologics License
Application (BLA)](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber) and", "api_data": null, "hint": null}, {"title": "FDA
Decisions to Look For in 1H 2026 | CGTlive\u00ae", "url": "https://www.cgtlive.com/view/fda-decisions-look-1h-2026", "snippet": "![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/9b1b40bc81fc00eeb
21179fe80ec2a22d6af7e25-800x500.jpg?w=350&fit=crop&auto=format)\n![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/9b1b40bc81fc00eeb21179fe80ec2a22d6af7e25-
800x500.jpg?w=350&fit=crop&auto=format)\nWe highlighted a few cell and gene therapies that are nearing or likely nearing key FDA decisions in the first half of 2026.\nAs 2026 kicks off, CGTLive\u00ae
is taking a look ahead at some of the most noteworthy cell and gene therapy p", "api_data": null, "hint": null}, {"title": "FDA Drug Approval Decisions Expected in January 2026 - Rheumatology
Advisor", "url": "https://www.rheumatologyadvisor.com/news/fda-drug-approval-decisions-expected-in-january-2026/", "snippet": "The [Prescription Drug User Fee Act
(PDUFA)](https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a [New
Drug Application (NDA)](https://www.fda.gov/drugs/types-applications/new-drug-application-nda) or [Biologics License Application (BLA)](https://www.fda.gov/vaccines-blood-biologics/development-
approval-process-cber/biologics-license-applications-bla-process-cber) and", "api_data": null, "hint": null}, {"title": "AAV Gene Therapy and the 2026 CMC Cliff \u2014 BLA Regulatory", "url":
"https://bla-regulatory.com/aav-gene-therapy-2026-cmc-cliff/", "snippet": "Navigating the 2026 \"CMC Cliff\" for AAV Gene Therapy\nJanuary 15, 2026\nAdeno-associated virus (AAV) gene therapy is one of
the most promising, yet most closely scrutinized modalities reviewed by the FDA. As we settle into early 2026, the AAV gene therapy sector has entered a defining moment. The narrative has shifted from
\u201ccan we cure it?\u201d to \u201ccan we make it consistently?\u201d For regulatory marketing professionals and biotech stakeholders, the data is unequivocal: clinical efficacy is no longer the ",
"api_data": null, "hint": null}, {"title": "FDA Drug Approval Decisions Expected in January 2026 - The Cardiology Advisor", "url": "https://www.thecardiologyadvisor.com/news/fda-drug-approval-
decisions-expected-in-january-2026/", "snippet": "The [Prescription Drug User Fee Act (PDUFA)](https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments) date refers to
the deadline set by the US Food and Drug Administration (FDA) for reviewing a [New Drug Application (NDA)](https://www.fda.gov/drugs/types-applications/new-drug-application-nda) or [Biologics License
Application (BLA)](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber) and", "api_data": null, "hint": null}, {"title": "New
drugs approved in the United States - Our World in Data", "url": "https://ourworldindata.org/grapher/new-drugs-approved-in-the-united-states", "snippet": "New drugs approved in the United
States\n![](/grapher/new-drugs-approved-in-the-united-states.png)\nWhat you should know about this indicator\nThis data includes both new drug applications (NDAs) and biologics license applications
(BLAs) approved by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) of the FDA.\n[with major
processing](https://ourworldindata.org#sources-and-processing)by Our World in Data\nWhat you should know about this ind", "api_data": null, "hint": null}, {"title": "Top FDA Gene and Cell Therapy
News: 2025 Year-End Recap | CGTlive\u00ae", "url": "https://www.cgtlive.com/view/top-fda-gene-cell-therapy-news-2025-year-end-recap", "snippet": "![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/
9b1b40bc81fc00eeb21179fe80ec2a22d6af7e25-800x500.jpg?w=350&fit=crop&auto=format)\n![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/9b1b40bc81fc00eeb21179fe80ec2a22d6af7e25-
800x500.jpg?w=350&fit=crop&auto=format)\nRecapping some the FDA approvals and regulatory updates in cell and gene therapy that made waves in 2025.\nAs 2025 comes to a close, CGTLive has looked back on
some of the most-read and most impactful FDA regulatory decisions and n", "api_data": null, "hint": null}, {"title": "FDA Outlines Flexible Approach to CMC Oversight for Cell and Gene Therapies |
OncLive", "url": "https://www.onclive.com/view/fda-outlines-flexible-approach-to-cmc-oversight-for-cell-and-gene-therapies", "snippet": null, "api_data": null, "hint": null}]}
```

## 💭 Thinking

Let me analyze this meta-prediction question carefully.

**Key facts:**
- This is a meta-prediction: Will the CP for question 41169 be higher than 27.00% on 2026-03-13?
- Current CP as of 2026-03-01: 27.00%
- The threshold is exactly 27.00% (strictly higher than)
- Resolution date: 2026-03-13 15:41:01
- Question published: 2026-03-03
- Question closes: 2026-03-03 20:21:27 (today!)
- 743 forecasters on the underlying question


- The CP sitting exactly at the threshold means any upward movement resolves YES, while staying flat or declining resolves NO.

I couldn't retrieve the CP history due to an access error, but I'm working through what I know about the underlying question: it's asking whether a gene editing therapy will be approved for a new condition in 2026. From my research, I don't see any CRISPR or gene editing therapies with FDA PDUFA dates scheduled for 2026 for novel indications, and the FDA's regulatory pathway for these treatments suggests approval is unlikely within this timeframe.

The real question now is whether the recent FDA announcement about a "plausible mechanism pathway" for personalized gene editing therapies—announced in late February—will shift forecaster sentiment upward over the next 10 days. With 743 forecasters already pricing this at exactly 27%, the market is essentially balanced, so I'm weighing whether this regulatory development is significant enough to push the CP above that threshold. so it's recent news about a draft pathway that's bullish for gene editing but unlikely to trigger an actual approval in 2026. The question spans the full year with 9+ months still remaining, so there's time for developments, though the CP being exactly at the 27% threshold makes this nearly a coin flip. I'm noticing the meta-question format might be auto-generated to match the current CP, which is worth considering when evaluating whether forecasters will shift their estimates upward based on the FDA pathway news. id":40897,"last_cp":0.27}}` - this confirms the meta-question threshold was set exactly at the last CP of 27%.

So the question is essentially: "Will the CP rise at all from its current level in the next 10 days?"

For a question with 743 forecasters about gene editing therapy approval in 2026:
- The CP could drift slightly in either direction
- News about the FDA's new pathway (Feb 23) may have already been incorporated
- No major imminent catalysts for gene editing approvals in the next 10 days

I think this is genuinely close to 50/50, with perhaps a very slight lean toward YES because:
- CP can fluctuate randomly, and any fluctuation upward counts
- The recent FDA pathway news is modestly positive for the underlying question
- New forecasters joining might have slightly different views

But there's also a slight lean toward NO because the CP has likely already absorbed recent news, with many forecasters keeping it stable, and no imminent approval catalysts are on the horizon. The resolution criteria requiring "higher than 27.00%" means even staying at exactly 27% resolves NO, so the status quo actually favors a NO resolution. I'm settling on around 45% probability for YES given that the CP needs to move upward rather than just hold steady. 743 forecasters and continuous updates over 10 days, the CP will almost certainly not remain exactly 27.00%. It will fluctuate. The question is whether it ends up above or below 27.00% on the snapshot date.

Given no strong directional catalyst, the probability of being above vs below the current level is roughly 50/50. But there's a very small asymmetry: "strictly higher than 27.00%" means we need the CP to be at least 27.01% or whatever the precision is.

I think approximately 50% is right, maybe slightly below because of the strict inequality. Let me estimate 48%.

The FDA's new gene editing pathway announced in late February 2026 is genuinely positive news, and some forecasters may gradually incorporate this over the next 10 days, which could push the CP slightly upward. However, the pathway is specifically for personalized therapies in ultra-rare diseases rather than standard approvals, and it's only draft guidance, so actual approvals through this route are still distant. That tempers the upward momentum. I'll settle on approximately 48-50%.

## 💬 Response

Now let me search for any very recent news that could shift forecaster sentiment on gene editing therapy approvals.

## 🔧 Tool: mcp__search__search_exa


## 🔧 Tool: mcp__search__web_search


```json
{
  "query": "CRISPR gene editing therapy new approval 2026 FDA MHRA EMA",
  "num_results": 5
}
```

### 📋 Result

```
Search failed: Client error '400 Bad Request' for url 'https://api.exa.ai/search'
For more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/400
```

```json
{
  "query": "Verve Therapeutics Intellia CRISPR FDA filing 2026"
}
```

### 📋 Result

```
{"query": "Verve Therapeutics Intellia CRISPR FDA filing 2026", "results": [{"title": "FDA lifts hold on an Intellia CRISPR drug trial | BioPharma Dive", "url":
"https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/", "snippet": null, "api_data": null, "hint": null}, {"title": "FDA places formal hold on two Intellia
CRISPR trials | BioPharma Dive", "url": "https://www.biopharmadive.com/news/intellia-fda-clinical-hold-crispr-nexiguran-ziclumeran-ttr-amyloidosis/804229/", "snippet": null, "api_data": null, "hint":
null}, {"title": "The CRISPR safety reset: what Intellia\u2019s lifted FDA hold really means for one-and-done gene editing -", "url": "https://www.industryexaminer.com/the-crispr-safety-reset-what-
intellias-lifted-fda-hold-really-means-for-one-and-done-gene-editing/", "snippet": null, "api_data": null, "hint": null}, {"title": "Verve gets FDA green light to run base editing study in US |
BioPharma Dive", "url": "https://www.biopharmadive.com/news/verve-fda-lift-hold-ind-clearance-base-editing-trial/697419/", "snippet": null, "api_data": null, "hint": null}, {"title": "Intellia
Therapeutics Eyes 2026 Pivotal CRISPR Milestone - TipRanks.com", "url": "https://www.tipranks.com/news/company-announcements/intellia-therapeutics-eyes-2026-pivotal-crispr-milestone", "snippet": null,
"api_data": null, "hint": null}, {"title": "FDA frees Verve's base editing therapy from clinical hold", "url": "https://www.fiercebiotech.com/biotech/verves-base-editing-hold-lifted-starting-thaw-
regulatory-blockade-sent-peers-ex-us", "snippet": "A nearly year-long clinical hold on Verve Therapeutics\u2019 base editing therapy meant to treat a genetic form of high cholesterol has been lifted
in the U.S., thanks to data from an ongoing human trial elsewhere in the world and some preclinical work that has allayed the FDA\u2019s concerns.\n\u201cThe combination of the human data and
addressing the preclinical questions did the trick,\u201d CEO Sekar Kathiresan, M.D., told Fierce Biotech in an interview.\nVERVE-101, which is in development for heterozygous famili", "api_data":
null, "hint": null}, {"title": "Verve\u2019s second swing at gene editing for heart disease shows early promise | BioPharma Dive", "url": "https://www.biopharmadive.com/news/verve-pcsk9-gene-editing-
hefh-study-results/745245/", "snippet": null, "api_data": null, "hint": null}, {"title": "FDA clears Intellia to start US tests of \u2018in vivo\u2019 gene editing drug | BioPharma Dive", "url":
"https://www.biopharmadive.com/news/intellia-fda-crispr-in-vivo-gene-editing-ind/643999/", "snippet": null, "api_data": null, "hint": null}, {"title": "CRISPR Clinical Trials: A 2025 Update -
Innovative Genomics Institute (IGI)", "url": "https://innovativegenomics.org/news/crispr-clinical-trials-2025/", "snippet": "![](https://innovativegenomics.org/wp-content/uploads/2025/06/clinical-
trials-2025-header-v1.jpg)\nFor [CRISPR](https://innovativegenomics.org/glossary/crispr/) clinical trials, 2025 seems like the best of times and the worst of times.\nThe best: a year and half ago, we
saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent [beta thalassemia](https://innovativegenomics.org/glossary/beta-
thalassemia/) (TBT). Since then, 50 activ", "api_data": null, "hint": null}, {"title": "News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine",
"url": "https://crisprmedicinenews.com/news/eli-lilly-to-acquire-verve-therapeutics-to-advance-one-time-cardiovascular-treatments/", "snippet": "Eli Lilly to Acquire Verve Therapeutics to Advance One-
Time Cardiovascular Treatments\nCMN Intelligence - The World\u2019s Most Comprehensive Intelligence Platform for CRISPR-Genomic Medicine and Gene-Editing Clinical Development\nProviding market
intelligence, data infrastructure, analytics, and reporting services for the global gene-editing sector. Read[ more...](https://crisprmedicinenews.com/cmn-intelligence/)\nEli Lilly and Verve
Therapeutics announced today that Lilly will acquire Verve for up to ", "api_data": null, "hint": null}]}
```

## 🔧 Tool: mcp__search__fetch_url


```json
{
  "url": "https://www.tipranks.com/news/company-announcements/intellia-therapeutics-eyes-2026-pivotal-crispr-milestone",
  "prompt": "What is the timeline for Intellia's CRISPR therapy reaching pivotal trial or FDA approval? When might they file for approval?"
}
```

### 📋 Result

```
HTTP 403 for https://www.tipranks.com/news/company-announcements/intellia-therapeutics-eyes-2026-pivotal-crispr-milestone. Access denied. Try search_exa for cached content, search_news for articles,
or a primary data source (fred_series, company_financials, world_bank_indicator).
```

## 🔧 Tool: mcp__search__fetch_url


```json
{
  "url": "https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/",
  "prompt": "What is the status of Intellia's CRISPR therapy for TTR amyloidosis? When might they file for FDA approval? What is the timeline?"
}
```

### 📋 Result

```
HTTP 403 for https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/. Access denied. Try search_exa for cached content, search_news for articles, or a primary
data source (fred_series, company_financials, world_bank_indicator).
```

## 🔧 Tool: mcp__search__web_search


## 🔧 Tool: mcp__search__web_search


```json
{
  "query": "Intellia nex-z nexiguran ziclumeran pivotal trial BLA filing timeline 2026 2027"
}
```

### 📋 Result

```
{"query": "Intellia nex-z nexiguran ziclumeran pivotal trial BLA filing timeline 2026 2027", "results": [{"title": "Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran
Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics", "url": "https://ir.intelliatx.com/news-releases/news-release-
details/intellia-therapeutics-announces-positive-longer-term-phase-1", "snippet": null, "api_data": null, "hint": null}, {"title": "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025
Financial Results and Business Updates", "url": "https://www.globenewswire.com/news-release/2026/02/26/3245466/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-
and-Business-Updates.html", "snippet": "- HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027\n-
Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026\n- FDA engagement ongoing to resolve
clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM\n- Ended 2025 with approximately $605 million in cash, cash equivalents and ma", "api_data": null, "hint": null}, {"title":
"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM", "url": "https://www.globenewswire.com/news-release/2026/03/02/3247267/0/en/Intellia-
Therapeutics-Announces-FDA-Lift-of-Clinical-Hold-on-MAGNITUDE-Phase-3-Clinical-Trial-in-ATTR-CM.html", "snippet": "CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
(Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug
Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with
transthyretin amyloidosis with card", "api_data": null, "hint": null}, {"title": "Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for
Hereditary Angioedema - Intellia Therapeutics", "url": "https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-completes-enrollment-global-phase-3-haelo", "snippet": null,
"api_data": null, "hint": null}, {"title": "Investigating Gene Therapy Nexiguran Ziclumeran for ATTRv-PN: Phase 3 MAGNITUDE-2 Trial | NeurologyLive - Clinical Neurology News and Neurology Expert
Insights", "url": "https://www.neurologylive.com/view/investigating-gene-therapy-nexiguran-ziclumeran-phase-3-study-attrv-pn-magnitude-2-trial", "snippet": null, "api_data": null, "hint": null},
{"title": "INTELLIA THERAPEUTICS Corporate Overview January 2026", "url": "https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e", "snippet": null, "api_data": null, "hint":
null}, {"title": "Press Releases - Intellia Therapeutics", "url": "https://ir.intelliatx.com/press-releases", "snippet": null, "api_data": null, "hint": null}, {"title": "StockWatch: Intellia Shares
Sink as Clinical Hold Follows Safety Setback", "url": "https://www.genengnews.com/topics/genome-editing/stockwatch-intellia-shares-sink-as-clinical-hold-follows-safety-setback/", "snippet": null,
"api_data": null, "hint": null}, {"title": "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics", "url":
"https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-provides-update-magnitude-clinical-trials", "snippet": null, "api_data": null, "hint": null}, {"title": "Intellia
Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics", "url": "https://ir.intelliatx.com/news-releases/news-release-details/intellia-
therapeutics-announces-fourth-quarter-and-full-year-8", "snippet": null, "api_data": null, "hint": null}]}
```

```json
{
  "query": "CRISPR base editing gene editing clinical trials phase 3 near approval 2026"
}
```

### 📋 Result

```
{"query": "CRISPR base editing gene editing clinical trials phase 3 near approval 2026", "results": [{"title": "Overview CRISPR Clinical Trials 2026 - Learn | Innovate | Access", "url":
"https://crisprmedicinenews.com/clinical-trials/", "snippet": "Gene-editing Clinical Trials\n**[The new CMN Global Trials Database 2.0 is now available](https://crisprmedicinenews.com/trialdb/)**\nIn
2023, therapeutic gene editing moved from promise to reality with the first approved CRISPR-based therapy, CASGEVY, which has since received regulatory clearance in multiple regions for the treatment
of sickle cell disease and beta thalassemia.\nOur manually curated CRISPR Medicine News Clinical Trials register tracks the advancement of gene-editing technologies i", "api_data": null, "hint":
null}, {"title": "Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/", "snippet":
"Abstract\nGenome editing has recently evolved from a theoretical concept to a powerful and versatile set of tools. The discovery and implementation of CRISPR-Cas9 technology have propelled the field
further into a new era. This RNA-guided system allows for specific modification of target genes, offering high accuracy and efficiency. Encouraging results are being announced in clinical trials
employed in conditions like sickle cell disease (SCD) and transfusion-dependent beta-thalassaemia (TDT). Th", "api_data": null, "hint": null}, {"title": "CRISPR Clinical Trials: A 2025 Update -
Innovative Genomics Institute (IGI)", "url": "https://innovativegenomics.org/news/crispr-clinical-trials-2025/", "snippet": "![](https://innovativegenomics.org/wp-content/uploads/2025/06/clinical-
trials-2025-header-v1.jpg)\nFor [CRISPR](https://innovativegenomics.org/glossary/crispr/) clinical trials, 2025 seems like the best of times and the worst of times.\nThe best: a year and half ago, we
saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent [beta thalassemia](https://innovativegenomics.org/glossary/beta-
thalassemia/) (TBT). Since then, 50 activ", "api_data": null, "hint": null}, {"title": "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results | CRISPR
Therapeutics", "url": "https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-third-6", "snippet": null, "api_data": null, "hint": null},
{"title": "CRISPR Clinical Trials to Follow", "url": "https://www.synthego.com/blog/crispr-clinical-trials/", "snippet": "In 2023, we entered the second decade of the CRISPR revolution, and saw the
[approval of Casgevy](https://ir.crisprtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-us-fda-approval), the first CRISPR-based medicine to become widely available.
The last several years have seen a marked increase in the number of genomic medicines in clinical development, and more of these candidates are pushing into the clinic for the first time. So how many
CRISPR clinical trials ar", "api_data": null, "hint": null}, {"title": "UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies", "url":
"https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies", "snippet": "After teasing a new regulatory process for personalized genetic medicines at the end of
last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, like the one that treated critically ill baby KJ last year, formally embraced by the
agency.\nFor now, the new pathway focuses on genome editing and RNA-based methods\u2014like antisense oligonucleotides\u2014that target the underlying cause of a rare disease, the FDA said in a [Feb.
23 release](https://www.f", "api_data": null, "hint": null}, {"title": "Future of CRISPR: Gene Editing Technologies Herald Landmark Clinical Trials", "url":
"https://www.infectiousdiseaseadvisor.com/features/future-of-crispr/", "snippet": "Clustered regularly interspaced short palindromic repeats (CRISPR), building on earlier-developed techniques such as
zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), has emerged as the most frequently used method of genome editing, with many new studies and trials gaining
traction.1\nCRISPR technology includes a variety of methods, each suitable for different applications.2 CRISPR-Cas9, derived from the immune system of Streptococcus pyogenes bacteria, is", "api_data":
null, "hint": null}, {"title": "Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond: Cell Reports Medicine", "url": "https://www.cell.com/cell-reports-
medicine/fulltext/S2666-3791(25)00532-4", "snippet": null, "api_data": null, "hint": null}, {"title": "Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across
diverse diseases - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12395446/", "snippet": "Abstract\nGene editing is a groundbreaking therapeutic approach that can potentially treat a broad
spectrum of genetic and acquired diseases. This review highlights recent clinical trials employing advanced gene editing technologies such as CRISPR-Cas9, zinc-finger nucleases (ZFNs), and base
editors across multiple disease areas including metabolic disorders, autoimmune diseases, muscular dystrophies, and inherited eye disorders. Central to the success of these therapies is the
development of eff", "api_data": null, "hint": null}, {"title": "Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 - American College of Cardiology", "url": "https://www.acc.org/latest-in-
cardiology/clinical-trials/2025/11/23/20/14/crispr-cas9", "snippet": "Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 - CRISPR-Cas9\nContribution To Literature:\nA one-time infusion of an
investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by approximately 55%, based on findings
from the CRISPR-Cas9 trial.\nStudy Design:\n- Total number of enrollees: 15 participants\n- Duration of follow-up: 60 days\n- Intervention: CTX310 at dose 0.1, 0.3, 0.6, 0.7 o", "api_data": null,
"hint": null}]}
```

## 💭 Thinking

This is very informative. Let me analyze the key findings:

1. **Intellia's lonvo-z (lonvoguran ziclumeran) for HAE (hereditary angioedema)**: Phase 3 HAELO data expected by mid-2026, BLA submission in second half of 2026, anticipated US launch first half of 2027. This is the closest gene editing therapy to approval for a NEW condition.

2. **Intellia's nex-z (nexiguran ziclumeran) for ATTR amyloidosis**: Phase 3 trials (MAGNITUDE and MAGNITUDE-2). The FDA just lifted the clinical hold on MAGNITUDE on March 2, 2026. 

The nex-z program is still enrolling patients in its Phase 3 studies.

3. **FDA's new "plausible mechanism pathway"** for personalized gene editing: Draft guidance announced Feb 23, 2026. This could theoretically enable faster approvals for personalized CRISPR therapies.

Looking at the timeline more carefully, lonvo-z's BLA submission in H2 2026 means FDA approval would realistically come in 2027, not 2026. There's no gene editing therapy with an actual PDUFA date in 2026. The only way we'd see a 2026 approval would be through an emergency authorization under that new plausible mechanism pathway.

An unexpected accelerated approval of something already in late-stage trials is theoretically possible but seems unlikely. The 27% confidence level feels about right for this underlying scenario.

Now thinking about whether the market probability moves above 27% by March 13. The recent news has been modestly positive—the clinical hold lift on nex-z, the BLA submission announcement, and the new FDA guidance—but none of it signals an imminent 2026 approval. These developments might nudge the probability up slightly, but probably not dramatically. upward. But none of these mean an actual approval is imminent.

The fact that Intellia plans to submit a BLA for lonvo-z (gene editing for HAE) in H2 2026 is notable. If submitted and given priority review, an approval in late 2026 is theoretically possible but unlikely (priority review is 6 months, standard is 10 months).

So the underlying probability might nudge up slightly, which could push CP above 27%. But it could also stay flat if forecasters have already incorporated this information.

**My assessment for the meta-prediction:**
- CP is exactly at the threshold (27.00%)
- Recent news is modestly positive (FDA pathway, Intellia BLA filing planned H2 2026, clinical hold lifted)
- These could push CP slightly up
- But forecasters may have already incorporated these developments (many happened before March 1)

With 743 forecasters and only a 10-day window, the market is relatively stable. The key question is whether the March 2 clinical hold lift—the most recent catalyst—will move the needle. Since the major developments happened before March 1 when CP was already at 27%, most of the positive sentiment may already be priced in. However, the clinical hold lift on the Phase 3 MAGNITUDE trial is fresh news that could provide a modest upward push. I'm leaning slightly toward YES, around 52-55%, though I need to be careful not to overweight a Phase 3 milestone as a proxy for approval probability. The real question is whether random market fluctuations will push the probability above that 27% threshold over the next 10 days. With no major catalysts expected and only marginally positive recent news, I'm settling on roughly 50-52% probability that it moves higher.

## 💬 Response

Now I have a good picture of the landscape. Let me also check if there's a Manifold or Polymarket equivalent for calibration.

## 🔧 Tool: mcp__markets__manifold_price


```json
{
  "query": "gene editing therapy approval 2026 CRISPR",
  "limit": 3
}
```

### 📋 Result

```
{"markets": [], "query": "gene editing therapy approval 2026 CRISPR"}
```

## 💬 Response

No cross-platform markets. Let me now synthesize my analysis and run the reflection.

**Summary of key findings:**

1. **CP at threshold exactly (27.00%)** — the meta-question threshold was auto-generated at the current CP
2. **743 forecasters** — relatively stable CP base
3. **10-day horizon** (March 3 → March 13)
4. **No gene editing therapy has a PDUFA date in 2026** — the closest is Intellia's lonvo-z (for HAE), with BLA submission planned H2 2026, meaning any approval would likely be 2027
5. **Recent positive catalysts already occurred before the CP snapshot (March 1)**: FDA "plausible mechanism pathway" (Feb 23), Intellia Q4 results (Feb 26)
6. **One very recent catalyst**: FDA lifted clinical hold on Intellia's MAGNITUDE trial for ATTR-CM (March 2, 2026) — but this is still about a Phase 3 trial, not an imminent approval
